Europe — EMA
Omvoh (Mirikizumab)
Mirikizumab, the active ingredient in Omvo, is a monoclonal antibody presented as a solution for intravenous infusion use. It targets inflammatory pathways and is indicated for adults with moderate to severe ulcerative…
Request sourcing
What is Mirikizumab?
Mirikizumab, the active ingredient in Omvo, is a monoclonal antibody presented as a solution for intravenous infusion use. It targets inflammatory pathways and is indicated for adults with moderate to severe ulcerative colitis who have had an adequate risk of treatment failure.
GNH USA supplies Omvo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.
What is Mirikizumab used for?
Omvo ... ... ... ... ... ... ... ... ... ... ... ... ... ...
- Ulcerative colitis ... … … … … ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... - … ...
